uniQure (NASDAQ:QURE) Rating Increased to Outperform at Royal Bank Of Canada

Royal Bank Of Canada upgraded shares of uniQure (NASDAQ:QURE) from a sector perform rating to an outperform rating in a research report report published on Monday, MarketBeat.com reports. They currently have $35.00 price target on the biotechnology company’s stock, up from their prior price target of $11.00.

A number of other brokerages have also recently issued reports on QURE. Stifel Nicolaus set a $14.00 target price on shares of uniQure in a research report on Monday, March 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of uniQure in a research report on Wednesday, January 21st. William Blair reissued a “market perform” rating on shares of uniQure in a research note on Tuesday, November 11th. Cantor Fitzgerald restated a “neutral” rating and set a $9.00 price objective (down from $55.00) on shares of uniQure in a research report on Monday, March 2nd. Finally, Mizuho reaffirmed a “neutral” rating and issued a $12.00 target price (down from $33.00) on shares of uniQure in a research note on Tuesday, March 3rd. Nine research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $41.33.

uniQure Trading Up 26.1%

Shares of QURE stock opened at $17.99 on Monday. The stock has a market cap of $1.12 billion, a P/E ratio of -5.21 and a beta of 0.73. The company has a quick ratio of 10.43, a current ratio of 10.43 and a debt-to-equity ratio of 0.25. uniQure has a fifty-two week low of $7.76 and a fifty-two week high of $71.50. The business has a fifty day simple moving average of $21.90 and a 200-day simple moving average of $29.64.

uniQure (NASDAQ:QURE) last released its quarterly earnings data on Monday, March 2nd. The biotechnology company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.93) by $0.37. The business had revenue of $5.57 million for the quarter, compared to analyst estimates of $4.84 million. uniQure had a negative net margin of 1,236.00% and a negative return on equity of 174.03%. On average, analysts forecast that uniQure will post -3.75 earnings per share for the current fiscal year.

Insider Activity at uniQure

In other news, CEO Matthew C. Kapusta sold 14,581 shares of uniQure stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total value of $132,103.86. Following the transaction, the chief executive officer directly owned 660,658 shares of the company’s stock, valued at $5,985,561.48. The trade was a 2.16% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Jeannette Potts sold 3,412 shares of the business’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total value of $30,912.72. Following the sale, the insider owned 138,483 shares of the company’s stock, valued at $1,254,655.98. The trade was a 2.40% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 81,399 shares of company stock valued at $1,527,645 over the last three months. Insiders own 4.79% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the business. Avoro Capital Advisors LLC lifted its position in uniQure by 38.4% during the fourth quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock valued at $147,170,000 after buying an additional 1,705,556 shares in the last quarter. Aberdeen Group plc increased its position in shares of uniQure by 25.1% in the fourth quarter. Aberdeen Group plc now owns 3,678,640 shares of the biotechnology company’s stock worth $88,030,000 after acquiring an additional 738,897 shares in the last quarter. State Street Corp increased its position in shares of uniQure by 123.8% in the fourth quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company’s stock worth $77,319,000 after acquiring an additional 1,787,033 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of uniQure by 155.3% in the 4th quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company’s stock valued at $70,226,000 after acquiring an additional 1,785,275 shares during the period. Finally, Jefferies Financial Group Inc. acquired a new position in shares of uniQure during the 2nd quarter valued at $29,217,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

uniQure News Roundup

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Analyst upgrades and price‑target increases lifting sentiment — Wells Fargo upgraded QURE to “overweight” with a $60 PT and Chardan boosted its PT to $31 with a buy rating; RBC moved to “outperform” with a $35 PT. These calls drove constructive re‑ratings and buy-side interest. Wells Fargo Upgrade Chardan PT Raise
• Positive Sentiment: Regulatory leadership change in the FDA (CBER director Vinay Prasad’s announced exit) is being interpreted by the market as easing near‑term regulatory risk for gene‑therapy programs, prompting a sector rally that lifted uniQure shares. Blockonomi: Stock Soars on FDA Exit Benzinga: Biotech Reaction
• Neutral Sentiment: Analyst and media coverage is spotlighting uniQure ahead of key AMT‑130 catalysts; these pieces increase visibility but do not change fundamentals absent clinical or regulatory news. 24/7 Wall St. Analyst Interest
• Negative Sentiment: Multiple law firms have filed or publicized investor notices seeking lead plaintiffs for a securities class action covering Sept. 24–Oct. 31, 2025 (claims tied to AMT‑130 disclosures). The proliferation of filings (Faruqi, Hagens Berman, Levi & Korsinsky, Portnoy, Rosen) creates legal and disclosure risk and could impose costs or settlement pressure. Faruqi & Faruqi Notice Hagens Berman Alert Levi & Korsinsky Notice Portnoy Law Firm Rosen Law Firm Notice
• Negative Sentiment: Coverage highlighting “confusion” and shifting narratives around uniQure’s disputes with the FDA over AMT‑130 suggests ongoing regulatory uncertainty that could weigh on valuation until resolved. The Pharma Letter: Confusion Grows Yahoo Finance: Shifting Narrative

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.